Shopping Cart 0
Cart Subtotal
USD 0

Evotec AG (EVT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides services such as integrated services, assay development and screening, reagent production services, ADMET, cellular target profiling, vitro pharmacology services and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and also has development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Manchester, the UK; Gottingen and Munich, Germany; South San Francisco, Branford and Princeton, the US; and Toulouse, France. Evotec is headquartered in Hamburg, Germany.

Evotec AG (EVT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 8

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14

Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Evotec AG, Pharmaceuticals & Healthcare, Deal Details 21

Venture Financing 21

Forge Therapeutics Raises USD15 million in Series A Financing 21

Eternygen Raises USD8.4 Million in Series A Financing 22

Carrick Therapeutics Raises USD95 Million in Venture Financing 23

Topas Therapeutics Raises USD15.8 Million in Series A Financing 25

Partnerships 27

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 27

Ferring Pharma and Evotec Enter into Research Partnership 28

Evotec and Almirall Enter into Research Agreement 29

Evotec and Celgene Enter into Partnership 30

Centogene and Evotec Enter into Co-Development Agreement 31

Evotec Enters into Co-Development Agreement with Novo Nordisk 32

Evotec Enters into R&D Agreement with Sanofi 33

Evotec and Artesian Therapeutics Enter into Agreement 34

Evotec and Oxford Bioscience Partners Enter into Co-Development Agreement 35

Evotec and Celgene Enter into Drug Discovery and Development Partnership 36

Evotec Enters into Partnership with Carna Biosciences 37

Evotec Enters into Partnership with Petra Pharma 38

Evotec Enters into Agreement with U3 Pharma 39

Evotec Enters into Research Agreement with Center for Regenerative Therapies Dresden 40

Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 41

Evotec and Tesaro Enter into Agreement 43

Forge Therapeutics and Evotec Enter into Partnership 44

Evotec and Abivax Enter into Partnership 45

Evotec Enters into Partnership with Fraunhofer 46

Evotec Enters into Agreement with Censo Biotech 47

Bioversys and Aptuit Enter into Partnership 48

Dementia Discovery Fund and Aptuit Enter into Partnership 49

Aptuit Enters into Agreement with Massachusetts General Hospital 50

Evotec Enters into Agreement with Asahi Kasei Pharma 51

Evotec Forms Joint Venture with MaRS Innovation 52

Chronos Therapeutics Partners with Aptuit 53

Aptuit Enters into Agreement with Chiesi Farmaceutici 54

Evotec Expands Agreement with Storm Therapeutics 55

Evotec Expands Research Agreement with Celgene 56

Evotec Enters into Agreement with Forge Therapeutics 57

Evotec Partners with Merck 58

Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 59

Evotec Enters into Agreement with C4X Discovery 60

Evotec Enters into Research Agreement with Inserm Transfert 61

Bayer Enters into Partnership with Evotec 62

Evotec Enters into Agreement with Antibiotic Research UK 63

Aptuit Enters into Agreement with Dimension Therapeutics 64

Trianni Enters into Agreement with Evotec 65

Evotec Forms Partnership with Ex Scientia 66

Evotec Partners with Pierre Fabre Labs 67

Icagen Partners with Aptuit 68

Evotec Partners with UCB 69

Evotec Extends its Agreement with Spero Therapeutics 70

Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 71

Evotec Enters into Research Agreement with Sanofi 72

Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 73

Evotec Enters into Agreement with Facio Therapies 74

Second Genome Enters into Agreement with Evotec 75

SAMDI Tech Enters into Agreement with Exquiron 76

Evotec Enters into Research Agreement with C4X Discovery 77

Evotec Enters into Research Agreement with Ohio State University 78

Evotec Extends Research Agreement with C4X Discovery 79

Evotec to Enter into Co-Development Agreement with Sanofi 80

Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 82

Rheumatech Enters into Development Agreement with Evotec 83

Euprotec Enters Into Agreement With Cantab Anti-infectives To Develop Antibiotics 84

Evotec Enters into Co-Development Agreement with Eternygen 85

Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 86

Evotec Enters into Agreement with Padlock Therapeutics 87

Evotec Extends Agreement with Padlock Therapeutics 88

Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 89

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 90

Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 91

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 92

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 93

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 94

Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 95

Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 96

Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 97

Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 98

Apredica Enters Into Research Agreement With Pfizer 99

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 100

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 101

Evotec Enters Into Co-Development Agreement With IR Pharma 102

Evotec Enters Into Co-Development Agreement With Harvard University And BWH 103

Licensing Agreements 105

Bayer Enters into Licensing Agreement with Haplogen and Evotec 105

Evotec Enters into Licensing Agreement with ERS Genomics 106

Evotec Enters into Licensing Agreement with Ncardia 107

Evotec Enters Into Licensing Agreement With Debiopharm 108

Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 109

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 110

Evotec Enters into Licensing Agreement with Broad Institute 112

Pfizer Enters into Licensing Agreement with Evotec 113

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 114

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 115

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 116

Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 118

Equity Offering 119

Facio Therapies Raises USD5.4 Million in Equity Financing 119

Evotec to Raise USD96.4 Million in Private Placement of Shares 120

Evotec Receives Investment from Ellersbrook 121

Evotec Spin Out from Topas Therapeutics 122

Evotec Completes Private Placement Of Shares For USD 40 Million 123

Asset Transactions 125

Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For USD 410 Million 125

Acquisition 126

Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 126

Evotec Acquires Aptuit for USD300 Million 127

Evotec Acquires Cyprotex for USD68 Million 129

Aptuit Acquires Kuecept 131

Aptuit Acquires Exquiron Biotech 132

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 133

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 134

Evotec Acquires Euprotec 135

Evotec Acquires Bionamics, Asset Management Company 136

Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To USD 6 Million 137

Evotec Acquires CCS Cell Culture Service, Contract Research Organization 138

Evotec Acquires DeveloGen For USD18 Million 139

Evotec AG - Key Competitors 141

Evotec AG - Key Employees 142

Evotec AG - Locations And Subsidiaries 143

Head Office 143

Other Locations & Subsidiaries 143

Joint Venture 144

Recent Developments 145

Financial Announcements 145

Aug 09, 2018: Evotec reports first half-year 2018 results and corporate updates 145

May 09, 2018: Evotec Reports First Quarter 2018 Results and Provides Corporate Update 149

Nov 08, 2017: Evotec announces first nine-month 2017 results and corporate update 151

Aug 10, 2017: Evotec Announces First Half Year 2017 Results 154

May 10, 2017: Evotec Announces First Quarter 2017 Results and Corporate Update 157

Mar 28, 2017: Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery 160

Government and Public Interest 164

Feb 21, 2017: Evotec: 'LAB282' awarded first projects 164

Product News 165

09/20/2017: Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS 165

Other Significant Developments 166

Mar 27, 2018: Evotec plans conversion into European Company (SE) 166

Mar 26, 2018: Evotec Launches INDIGO, A Unique Integrated Drug Development Solution for Accelerating Early Drug Candidates into the Clinic 167

Sep 08, 2017: European Investment Bank supports Evotecs Innovate strategy with 75 m loan 168

Appendix 169

Methodology 169

About GlobalData 169

Contact Us 169

Disclaimer 169


List Of Figure

List of Figures

Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Evotec AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Evotec AG, Deals By Therapy Area, 2012 to YTD 2018 12

Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14

Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Forge Therapeutics Raises USD15 million in Series A Financing 21

Eternygen Raises USD8.4 Million in Series A Financing 22

Carrick Therapeutics Raises USD95 Million in Venture Financing 23

Topas Therapeutics Raises USD15.8 Million in Series A Financing 25

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 27

Ferring Pharma and Evotec Enter into Research Partnership 28

Evotec and Almirall Enter into Research Agreement 29

Evotec and Celgene Enter into Partnership 30

Centogene and Evotec Enter into Co-Development Agreement 31

Evotec Enters into Co-Development Agreement with Novo Nordisk 32

Evotec Enters into R&D Agreement with Sanofi 33

Evotec and Artesian Therapeutics Enter into Agreement 34

Evotec and Oxford Bioscience Partners Enter into Co-Development Agreement 35

Evotec and Celgene Enter into Drug Discovery and Development Partnership 36

Evotec Enters into Partnership with Carna Biosciences 37

Evotec Enters into Partnership with Petra Pharma 38

Evotec Enters into Agreement with U3 Pharma 39

Evotec Enters into Research Agreement with Center for Regenerative Therapies Dresden 40

Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 41

Evotec and Tesaro Enter into Agreement 43

Forge Therapeutics and Evotec Enter into Partnership 44

Evotec and Abivax Enter into Partnership 45

Evotec Enters into Partnership with Fraunhofer 46

Evotec Enters into Agreement with Censo Biotech 47

Bioversys and Aptuit Enter into Partnership 48

Dementia Discovery Fund and Aptuit Enter into Partnership 49

Aptuit Enters into Agreement with Massachusetts General Hospital 50

Evotec Enters into Agreement with Asahi Kasei Pharma 51

Evotec Forms Joint Venture with MaRS Innovation 52

Chronos Therapeutics Partners with Aptuit 53

Aptuit Enters into Agreement with Chiesi Farmaceutici 54

Evotec Expands Agreement with Storm Therapeutics 55

Evotec Expands Research Agreement with Celgene 56

Evotec Enters into Agreement with Forge Therapeutics 57

Evotec Partners with Merck 58

Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 59

Evotec Enters into Agreement with C4X Discovery 60

Evotec Enters into Research Agreement with Inserm Transfert 61

Bayer Enters into Partnership with Evotec 62

Evotec Enters into Agreement with Antibiotic Research UK 63

Aptuit Enters into Agreement with Dimension Therapeutics 64

Trianni Enters into Agreement with Evotec 65

Evotec Forms Partnership with Ex Scientia 66

Evotec Partners with Pierre Fabre Labs 67

Icagen Partners with Aptuit 68

Evotec Partners with UCB 69

Evotec Extends its Agreement with Spero Therapeutics 70

Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 71

Evotec Enters into Research Agreement with Sanofi 72

Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 73

Evotec Enters into Agreement with Facio Therapies 74

Second Genome Enters into Agreement with Evotec 75

SAMDI Tech Enters into Agreement with Exquiron 76

Evotec Enters into Research Agreement with C4X Discovery 77

Evotec Enters into Research Agreement with Ohio State University 78

Evotec Extends Research Agreement with C4X Discovery 79

Evotec to Enter into Co-Development Agreement with Sanofi 80

Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 82

Rheumatech Enters into Development Agreement with Evotec 83

Euprotec Enters Into Agreement With Cantab Anti-infectives To Develop Antibiotics 84

Evotec Enters into Co-Development Agreement with Eternygen 85

Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 86

Evotec Enters into Agreement with Padlock Therapeutics 87

Evotec Extends Agreement with Padlock Therapeutics 88

Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 89

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 90

Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 91

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 92

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 93

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 94

Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 95

Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 96

Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 97

Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 98

Apredica Enters Into Research Agreement With Pfizer 99

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 100

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 101

Evotec Enters Into Co-Development Agreement With IR Pharma 102

Evotec Enters Into Co-Development Agreement With Harvard University And BWH 103

Bayer Enters into Licensing Agreement with Haplogen and Evotec 105

Evotec Enters into Licensing Agreement with ERS Genomics 106

Evotec Enters into Licensing Agreement with Ncardia 107

Evotec Enters Into Licensing Agreement With Debiopharm 108

Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 109

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 110

Evotec Enters into Licensing Agreement with Broad Institute 112

Pfizer Enters into Licensing Agreement with Evotec 113

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 114

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 115

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 116

Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 118

Facio Therapies Raises USD5.4 Million in Equity Financing 119

Evotec to Raise USD96.4 Million in Private Placement of Shares 120

Evotec Receives Investment from Ellersbrook 121

Evotec Spin Out from Topas Therapeutics 122

Evotec Completes Private Placement Of Shares For USD 40 Million 123

Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For USD 410 Million 125

Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 126

Evotec Acquires Aptuit for USD300 Million 127

Evotec Acquires Cyprotex for USD68 Million 129

Aptuit Acquires Kuecept 131

Aptuit Acquires Exquiron Biotech 132

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 133

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 134

Evotec Acquires Euprotec 135

Evotec Acquires Bionamics, Asset Management Company 136

Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To USD 6 Million 137

Evotec Acquires CCS Cell Culture Service, Contract Research Organization 138

Evotec Acquires DeveloGen For USD18 Million 139

Evotec AG, Key Competitors 141

Evotec AG, Key Employees 142

Evotec AG, Subsidiaries 143

Evotec AG, Joint Venture 144

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Evotec AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides services such as integrated services, assay development and screening, reagent production services, ADMET, cellular target profiling, vitro pharmacology services and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and also has development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Manchester, the UK; Gottingen and Munich, Germany; South San Francisco, Branford and Princeton, the US; and Toulouse, France. Evotec is headquartered in Hamburg, Germany.

Evotec AG (EVT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 8

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14

Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Evotec AG, Pharmaceuticals & Healthcare, Deal Details 21

Venture Financing 21

Forge Therapeutics Raises USD15 million in Series A Financing 21

Eternygen Raises USD8.4 Million in Series A Financing 22

Carrick Therapeutics Raises USD95 Million in Venture Financing 23

Topas Therapeutics Raises USD15.8 Million in Series A Financing 25

Partnerships 27

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 27

Ferring Pharma and Evotec Enter into Research Partnership 28

Evotec and Almirall Enter into Research Agreement 29

Evotec and Celgene Enter into Partnership 30

Centogene and Evotec Enter into Co-Development Agreement 31

Evotec Enters into Co-Development Agreement with Novo Nordisk 32

Evotec Enters into R&D Agreement with Sanofi 33

Evotec and Artesian Therapeutics Enter into Agreement 34

Evotec and Oxford Bioscience Partners Enter into Co-Development Agreement 35

Evotec and Celgene Enter into Drug Discovery and Development Partnership 36

Evotec Enters into Partnership with Carna Biosciences 37

Evotec Enters into Partnership with Petra Pharma 38

Evotec Enters into Agreement with U3 Pharma 39

Evotec Enters into Research Agreement with Center for Regenerative Therapies Dresden 40

Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 41

Evotec and Tesaro Enter into Agreement 43

Forge Therapeutics and Evotec Enter into Partnership 44

Evotec and Abivax Enter into Partnership 45

Evotec Enters into Partnership with Fraunhofer 46

Evotec Enters into Agreement with Censo Biotech 47

Bioversys and Aptuit Enter into Partnership 48

Dementia Discovery Fund and Aptuit Enter into Partnership 49

Aptuit Enters into Agreement with Massachusetts General Hospital 50

Evotec Enters into Agreement with Asahi Kasei Pharma 51

Evotec Forms Joint Venture with MaRS Innovation 52

Chronos Therapeutics Partners with Aptuit 53

Aptuit Enters into Agreement with Chiesi Farmaceutici 54

Evotec Expands Agreement with Storm Therapeutics 55

Evotec Expands Research Agreement with Celgene 56

Evotec Enters into Agreement with Forge Therapeutics 57

Evotec Partners with Merck 58

Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 59

Evotec Enters into Agreement with C4X Discovery 60

Evotec Enters into Research Agreement with Inserm Transfert 61

Bayer Enters into Partnership with Evotec 62

Evotec Enters into Agreement with Antibiotic Research UK 63

Aptuit Enters into Agreement with Dimension Therapeutics 64

Trianni Enters into Agreement with Evotec 65

Evotec Forms Partnership with Ex Scientia 66

Evotec Partners with Pierre Fabre Labs 67

Icagen Partners with Aptuit 68

Evotec Partners with UCB 69

Evotec Extends its Agreement with Spero Therapeutics 70

Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 71

Evotec Enters into Research Agreement with Sanofi 72

Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 73

Evotec Enters into Agreement with Facio Therapies 74

Second Genome Enters into Agreement with Evotec 75

SAMDI Tech Enters into Agreement with Exquiron 76

Evotec Enters into Research Agreement with C4X Discovery 77

Evotec Enters into Research Agreement with Ohio State University 78

Evotec Extends Research Agreement with C4X Discovery 79

Evotec to Enter into Co-Development Agreement with Sanofi 80

Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 82

Rheumatech Enters into Development Agreement with Evotec 83

Euprotec Enters Into Agreement With Cantab Anti-infectives To Develop Antibiotics 84

Evotec Enters into Co-Development Agreement with Eternygen 85

Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 86

Evotec Enters into Agreement with Padlock Therapeutics 87

Evotec Extends Agreement with Padlock Therapeutics 88

Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 89

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 90

Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 91

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 92

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 93

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 94

Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 95

Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 96

Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 97

Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 98

Apredica Enters Into Research Agreement With Pfizer 99

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 100

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 101

Evotec Enters Into Co-Development Agreement With IR Pharma 102

Evotec Enters Into Co-Development Agreement With Harvard University And BWH 103

Licensing Agreements 105

Bayer Enters into Licensing Agreement with Haplogen and Evotec 105

Evotec Enters into Licensing Agreement with ERS Genomics 106

Evotec Enters into Licensing Agreement with Ncardia 107

Evotec Enters Into Licensing Agreement With Debiopharm 108

Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 109

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 110

Evotec Enters into Licensing Agreement with Broad Institute 112

Pfizer Enters into Licensing Agreement with Evotec 113

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 114

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 115

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 116

Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 118

Equity Offering 119

Facio Therapies Raises USD5.4 Million in Equity Financing 119

Evotec to Raise USD96.4 Million in Private Placement of Shares 120

Evotec Receives Investment from Ellersbrook 121

Evotec Spin Out from Topas Therapeutics 122

Evotec Completes Private Placement Of Shares For USD 40 Million 123

Asset Transactions 125

Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For USD 410 Million 125

Acquisition 126

Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 126

Evotec Acquires Aptuit for USD300 Million 127

Evotec Acquires Cyprotex for USD68 Million 129

Aptuit Acquires Kuecept 131

Aptuit Acquires Exquiron Biotech 132

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 133

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 134

Evotec Acquires Euprotec 135

Evotec Acquires Bionamics, Asset Management Company 136

Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To USD 6 Million 137

Evotec Acquires CCS Cell Culture Service, Contract Research Organization 138

Evotec Acquires DeveloGen For USD18 Million 139

Evotec AG - Key Competitors 141

Evotec AG - Key Employees 142

Evotec AG - Locations And Subsidiaries 143

Head Office 143

Other Locations & Subsidiaries 143

Joint Venture 144

Recent Developments 145

Financial Announcements 145

Aug 09, 2018: Evotec reports first half-year 2018 results and corporate updates 145

May 09, 2018: Evotec Reports First Quarter 2018 Results and Provides Corporate Update 149

Nov 08, 2017: Evotec announces first nine-month 2017 results and corporate update 151

Aug 10, 2017: Evotec Announces First Half Year 2017 Results 154

May 10, 2017: Evotec Announces First Quarter 2017 Results and Corporate Update 157

Mar 28, 2017: Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery 160

Government and Public Interest 164

Feb 21, 2017: Evotec: 'LAB282' awarded first projects 164

Product News 165

09/20/2017: Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS 165

Other Significant Developments 166

Mar 27, 2018: Evotec plans conversion into European Company (SE) 166

Mar 26, 2018: Evotec Launches INDIGO, A Unique Integrated Drug Development Solution for Accelerating Early Drug Candidates into the Clinic 167

Sep 08, 2017: European Investment Bank supports Evotecs Innovate strategy with 75 m loan 168

Appendix 169

Methodology 169

About GlobalData 169

Contact Us 169

Disclaimer 169


List Of Figure

List of Figures

Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Evotec AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Evotec AG, Deals By Therapy Area, 2012 to YTD 2018 12

Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14

Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Forge Therapeutics Raises USD15 million in Series A Financing 21

Eternygen Raises USD8.4 Million in Series A Financing 22

Carrick Therapeutics Raises USD95 Million in Venture Financing 23

Topas Therapeutics Raises USD15.8 Million in Series A Financing 25

Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 27

Ferring Pharma and Evotec Enter into Research Partnership 28

Evotec and Almirall Enter into Research Agreement 29

Evotec and Celgene Enter into Partnership 30

Centogene and Evotec Enter into Co-Development Agreement 31

Evotec Enters into Co-Development Agreement with Novo Nordisk 32

Evotec Enters into R&D Agreement with Sanofi 33

Evotec and Artesian Therapeutics Enter into Agreement 34

Evotec and Oxford Bioscience Partners Enter into Co-Development Agreement 35

Evotec and Celgene Enter into Drug Discovery and Development Partnership 36

Evotec Enters into Partnership with Carna Biosciences 37

Evotec Enters into Partnership with Petra Pharma 38

Evotec Enters into Agreement with U3 Pharma 39

Evotec Enters into Research Agreement with Center for Regenerative Therapies Dresden 40

Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 41

Evotec and Tesaro Enter into Agreement 43

Forge Therapeutics and Evotec Enter into Partnership 44

Evotec and Abivax Enter into Partnership 45

Evotec Enters into Partnership with Fraunhofer 46

Evotec Enters into Agreement with Censo Biotech 47

Bioversys and Aptuit Enter into Partnership 48

Dementia Discovery Fund and Aptuit Enter into Partnership 49

Aptuit Enters into Agreement with Massachusetts General Hospital 50

Evotec Enters into Agreement with Asahi Kasei Pharma 51

Evotec Forms Joint Venture with MaRS Innovation 52

Chronos Therapeutics Partners with Aptuit 53

Aptuit Enters into Agreement with Chiesi Farmaceutici 54

Evotec Expands Agreement with Storm Therapeutics 55

Evotec Expands Research Agreement with Celgene 56

Evotec Enters into Agreement with Forge Therapeutics 57

Evotec Partners with Merck 58

Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 59

Evotec Enters into Agreement with C4X Discovery 60

Evotec Enters into Research Agreement with Inserm Transfert 61

Bayer Enters into Partnership with Evotec 62

Evotec Enters into Agreement with Antibiotic Research UK 63

Aptuit Enters into Agreement with Dimension Therapeutics 64

Trianni Enters into Agreement with Evotec 65

Evotec Forms Partnership with Ex Scientia 66

Evotec Partners with Pierre Fabre Labs 67

Icagen Partners with Aptuit 68

Evotec Partners with UCB 69

Evotec Extends its Agreement with Spero Therapeutics 70

Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 71

Evotec Enters into Research Agreement with Sanofi 72

Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 73

Evotec Enters into Agreement with Facio Therapies 74

Second Genome Enters into Agreement with Evotec 75

SAMDI Tech Enters into Agreement with Exquiron 76

Evotec Enters into Research Agreement with C4X Discovery 77

Evotec Enters into Research Agreement with Ohio State University 78

Evotec Extends Research Agreement with C4X Discovery 79

Evotec to Enter into Co-Development Agreement with Sanofi 80

Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 82

Rheumatech Enters into Development Agreement with Evotec 83

Euprotec Enters Into Agreement With Cantab Anti-infectives To Develop Antibiotics 84

Evotec Enters into Co-Development Agreement with Eternygen 85

Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 86

Evotec Enters into Agreement with Padlock Therapeutics 87

Evotec Extends Agreement with Padlock Therapeutics 88

Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 89

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 90

Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 91

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 92

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 93

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 94

Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 95

Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 96

Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 97

Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 98

Apredica Enters Into Research Agreement With Pfizer 99

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 100

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 101

Evotec Enters Into Co-Development Agreement With IR Pharma 102

Evotec Enters Into Co-Development Agreement With Harvard University And BWH 103

Bayer Enters into Licensing Agreement with Haplogen and Evotec 105

Evotec Enters into Licensing Agreement with ERS Genomics 106

Evotec Enters into Licensing Agreement with Ncardia 107

Evotec Enters Into Licensing Agreement With Debiopharm 108

Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 109

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 110

Evotec Enters into Licensing Agreement with Broad Institute 112

Pfizer Enters into Licensing Agreement with Evotec 113

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 114

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 115

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 116

Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 118

Facio Therapies Raises USD5.4 Million in Equity Financing 119

Evotec to Raise USD96.4 Million in Private Placement of Shares 120

Evotec Receives Investment from Ellersbrook 121

Evotec Spin Out from Topas Therapeutics 122

Evotec Completes Private Placement Of Shares For USD 40 Million 123

Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For USD 410 Million 125

Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 126

Evotec Acquires Aptuit for USD300 Million 127

Evotec Acquires Cyprotex for USD68 Million 129

Aptuit Acquires Kuecept 131

Aptuit Acquires Exquiron Biotech 132

Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 133

Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 134

Evotec Acquires Euprotec 135

Evotec Acquires Bionamics, Asset Management Company 136

Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To USD 6 Million 137

Evotec Acquires CCS Cell Culture Service, Contract Research Organization 138

Evotec Acquires DeveloGen For USD18 Million 139

Evotec AG, Key Competitors 141

Evotec AG, Key Employees 142

Evotec AG, Subsidiaries 143

Evotec AG, Joint Venture 144

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Evotec AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.